Study of Oral CNF2024 in Advanced Solid Tumors

Study of Oral CNF2024 in Advanced Solid Tumors

Tumors, Lymphoma

Completed

1

Start Date 02/01/2006

Age of Trial (yrs) 18.2

Gleevec-resistant

HSP90 inhibitor

Destroy KIT

GIST not specified. GIST patients known to be enrolled.

Biogen Idec

oncologyclinicaltrials@biogenidec.com

Oral

Contact: Biogen Idec, oncologyclinicaltrials@biogenidec.com
Note: When contacting please refer to this study by ClinicalTrials.gov identifier NCT00345189
Note: This is a single point of contact for all CNF2024 Phase I sites.
BIIB021 is an oral third-generation Hsp90 inhibitor and is manufactured by Biogen Idec. Phase II trials have started at Memorial Sloan-Kettering Cancer Center (New York, NY) and at the Mayo Clinic in Rochester, Minnesota. The phase II trial is specifically for GIST.

Heat shock protein 90 (Hsp90) is an ubiquitous molecular chaperone protein that is involved in folding, activation, and assembly of many proteins, including key mediators of signal transduction, cell cycle control, and transcriptional regulation. In cancer cells that are dependent upon Hsp90 client proteins, the degree to which clients are inhibited correlates closely with induction of growth inhibition and apoptosis with Hsp90 inhibitory drugs. The active pharmaceutical ingredient of CNF2024, CF1983 mesylate, is a synthetic, new chemical entity designed to inhibit Hsp90. CF1983 hada strong affinity for tumor derived Hsp90 and weaker affinity for Hsp90 isolated from normal cells or recombinant Hsp90.